Study S001199
A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)
Registration
Registered primary outcomes
- Change in HbA1c From Baseline to Week 30 [Baseline, Week 30]
Linked records (16)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0042144 | Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin >= 8%, >= 64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial Melanie J Davies (7258691), Figshare | 2023 | Randomized trial | cites ClinicalTrials.gov:NCT02058147 | |
| R0013783 | Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial. Davies MJ, Diabetes, obesity & metabolism | 2022 | Randomized trial | PMID 34617398DOI | cites ClinicalTrials.gov:NCT02058147 |
| R0015023 | Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study. Shao H, Journal of diabetes and its complications | 2022 | Nonrandomized study | PMID 35101326DOI | cites ClinicalTrials.gov:NCT02058147; registry reference DERIVED:35101326 |
| R0011584 | Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials. Davidson JA, Diabetic medicine : a journal of the British Diabetic Association | 2020 | Other trial | PMID 31365765DOI | cites ClinicalTrials.gov:NCT02058147 |
| R0007277 | EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES. Mora PF, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists | 2019 | Randomized trial | PMID 31241362DOI | cites ClinicalTrials.gov:NCT02058147 |
| R0012646 | Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes. Schmider W, Current medical research and opinion | 2019 | Other | PMID 30550345DOI | cites ClinicalTrials.gov:NCT02058147; registry reference DERIVED:30550345 |
| R0012665 | Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world. Dailey G, BMJ open diabetes research & care | 2019 | Nonrandomized study | PMID 31114694DOI | cites ClinicalTrials.gov:NCT02058147; registry reference DERIVED:31114694 |
| R0015993 | Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial. Davies MJ, Diabetes, obesity & metabolism | 2019 | Randomized trial | PMID 31124299DOI | cites ClinicalTrials.gov:NCT02058147; registry reference DERIVED:31124299 |
| R0009175 | Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. Rosenstock J, Diabetes, obesity & metabolism | 2018 | Nonrandomized study | PMID 29974618DOI | cites ClinicalTrials.gov:NCT02058147; registry reference DERIVED:29974618 |
| R0014110 | Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone. Trujillo JM, Diabetes, obesity & metabolism | 2018 | Other trial | PMID 29923298DOI | cites ClinicalTrials.gov:NCT02058147; registry reference DERIVED:29923298 |
| R0049204 | Relationship of Ethnicity to Clinical Outcomes in iGlarLixi-Treated Patients with Type 2 Diabetes Pablo Mora, Diabetes | 2018 | Other trial | DOI | cites ClinicalTrials.gov:NCT02058147 |
| R0051252 | Glycemic Target Attainment in Insulin-Naïve Patients with T2D Receiving iGlarLixi Cyrus V Desouza, Diabetes | 2018 | Other trial | DOI | cites ClinicalTrials.gov:NCT02058147 |
| R0012685 | Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents. Davies MJ, Diabetes, obesity & metabolism | 2017 | Other trial | PMID 28432746DOI | cites ClinicalTrials.gov:NCT02058147; registry reference DERIVED:28432746 |
| R0044406 | Low incidence of gastrointestinal adverse events over time with a combination of insulin glargine and lixisenatide Bowden Georgina | 2017 | Randomized trial | DOI | cites ClinicalTrials.gov:NCT02058147 |
| R0017964 | Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Rosenstock J, Diabetes care | 2016 | Randomized trial | PMID 27527848DOI | cites ClinicalTrials.gov:NCT02058147; registry reference RESULT:27527848 |
| R0045038 | Clinical Impact of Titratable Fixed-Ratio Combination of Insulin Glargine/Lixisenatide vs. Each Component Alone in Type 2 Diabetes Inadequately Controlled on Oral Agents: LixiLan-O Trial (NCT02058147) Ronnie Aronson, Canadian Journal of Diabetes | 2016 | Other trial | DOI | cites ClinicalTrials.gov:NCT02058147 |